Investment & Fund Management

Minoryx Therapeutics, a biotech company based in Spain, is dedicated to developing innovative therapies for rare diseases, particularly focusing on adrenoleukodystrophy (ALD), a genetic condition that can lead to severe health issues and currently has no cure. The company faced significant challenges in funding and advancing their research and clinical trials, which are critical for bringing new treatments to market.

To address these challenges, Minoryx secured investment from Ysios Capital, a venture capital firm supported by the European Investment Fund (EIF) under the EU’s Investment Plan for Europe. This funding was pivotal, enabling Minoryx to initiate regulatory pre-clinical activities and successfully complete a phase-1 clinical trial. The investment not only facilitated the company's growth—allowing them to double in size—but also positively impacted their network of service providers, including clinical study providers and regulatory advisors.

As a result of this tailored financial support, Minoryx is now advancing further clinical trials with the goal of obtaining marketing authorization for their therapies. The funding has significantly accelerated their research efforts and expanded their capabilities, positioning them to explore additional treatments for other rare diseases.